Earn 7 AMA PRA Category 1 CreditsTM
Date: Saturday, March 14, 2009
Time: 8:00 am-4:30 pm
Location: New York Marriott Marquis, New York City
Program Description
Prostate cancer is one of the most common types of cancer among men. There will be an estimated 219,000 new cases and approximately 27,000 deaths from this disease in the United States in 2008. On March 14, 2009, ArcMesa Educators, a fully accredited provider of continuing medical education (CME), will sponsor its 2nd Annual Interdisciplinary Prostate Cancer Congress (IPCC) at the Marriott Marquis Hotel in New York City. This full-day CME initiative will build on last year’s success by delivering a program specifically addressing the differences that currently exist between urologist’s, radiation oncologist’s, and medical oncologist’s approaches to treating prostate cancer. The urgency for this CME initiative is apparent by the elimination of a dedicated prostate cancer meeting by the American Society of Clinical Oncology (ASCO) in favor of one broadly focused on genitourinary disease management.
Leonard Gomella, MD and Daniel Petrylak, MD will return as co-chairs for this program. In addition, Roy Berger, MD, E. David Crawford, MD, Robert Dreicer, MD, Howard Sandler, MD, Oliver Sartor, MD, will serve as faculty members for this educational initiative. These world-renowned thought leaders have been brought together to foster consensus concerning the optimal management of prostate cancer from the vantage point of interdisciplinary care teams. Among several topics of vital interest to these groups of clinicians, the IPCC will address prostate cancer prevention, targeted focal therapies for localized prostate cancer, hormonal therapies, radiation therapies, osteoclast inhibition therapy for hormone-refractory patients and other emerging multi-modal therapies for the treatment of prostate cancer. The IPCC will conclude with a set of interactive case-based presentations designed to highlight a multidisciplinary approach for the management of prostate cancer with the overall goal of improving patient outcomes.
The primary audience for this educational program includes practicing urologists, radiation oncologists, medical oncologists and surgical oncologists since these caregivers comprise the majority of specialists who diagnose and treat patients with prostate cancer.
ArcMesa Educators will designate this full day educational activity for a maximum of 7 AMA PRA Category 1 credits™.
Topics
- Prostate Cancer Prevention
- Immune Therapy Approaches for Prostate Cancer: Is There a Role for Vaccine Therapy in the Treatment of Prostate Cancer?
- Screening for Prostate Cancer: New Tools and Markers
- Proton Beam Therapy and Other New Radiation Technologies
- Targeted Focal Therapy for Localized Prostate Cancer
- Management of Hormone Refractory Metastatic Prostate Cancer
- Osteoclast Inhibition Therapy: Relieving Pain From Bone Metastasis in Hormone Refractory Prostate Cancer
- Penile Rehabilitation After Radical Post Prostatectomy
- Prostate Cancer Care Teams: A Case-Based Approach
Accreditation & Credit Designation
ArcMesa Educators is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ArcMesa Educators designates this educational activity for a maximum of 7 AMA PRA Category 1 credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Learning Objectives
At the conclusion of this activity, participants will be able to:
- Review the current treatment options for patients with localized, androgen-dependent, and hormone refractory prostate cancer.
- Identify the disparities among current practice guidelines for the treatment of patients with prostate cancer.
- Evaluate the results of recent clinical trials investigating the efficacy and safety of emerging agents for the treatment of prostate cancer.
- Formulate an interdisciplinary plan for the treatment and management of patients with prostate cancer.
Target Audience
This activity is intended for urologists, radiation oncologists, surgical oncologists and medical oncologists who treat patients with prostate cancer.
Faculty Disclosures
Leonard G. Gomella, MD
Speakers’ Bureau: AstraZeneca
Consultant, Investigator: GlaxoSmithKline
Investigator: Dendreon
Daniel P. Petrylak, MD
Consultant, Grant/Research Support recipient: GPC Biotech, sanofi-aventis, Celgene, Cell Genesys, Dendreon
Honorarium: Sanofi-aventis
E. Roy Berger, MD, FACP
Speakers’ Bureau: Amgen, AstraZeneca, Dendreon, MGI Pharma, Novartis, sanofi-aventis, Schering-Plough
Advisory Board Member: Dendreon, Patient Advocates for Advanced Cancer Treatment
Consultant: Dendreon, MEDA, MD Rx, P4 Healthcare
E. David Crawford, MD
Nothing to disclose relative to this activity
Robert Dreicer, MD
Grant/Research Support Recipient: Bayer, Celgene, Lilly, sanofi-aventis
Howard M. Sandler, MD, MS
Honorarium: AstraZeneca, GPC Biotech, Amgen
A. Oliver Sartor, MD
Advisor or Review Panel Member, Consultant: Cytogen, Algeta, GPC-Biotech, sanofi-aventis, GlaxoSmithKline, Ausio
Staff Disclosure Declarations
The employees of ArcMesa Educators have no financial relationships to disclose.
|
Co-Chairs
Leonard G. Gomella, MD
The Bernard W. Godwin Professor of Prostate Cancer; Chairman, Department of Urology;
Associate Director of Clinical Affairs, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Daniel P. Petrylak, MD
Co-Director of Oncology Clinical Trials Network, Assistant Professor of Medicine;
Director of the Genitourinary Oncology Program in the Division of Medical Oncology, Columbia University College of Physicians and Surgeons, New York, NY.
Faculty
E. Roy Berger, MD, FACP
Assistant Clinical Professor, Department of Oncology, State University of New York, Stony Brook, NY.
E. David Crawford, MD
Professor of Surgery, Professor of Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Health Sciences Center;
Associate Director of the University of Colorado Comprehensive Cancer Center, Denver, CO.
Robert Dreicer, MD
Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Chairman, Department of Solid Tumors, Director of the Genitourinary Medical Oncology Program, and Associate Director of Experimental Therapeutics, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.
Howard M. Sandler, MD, MS
Chair, Department of Radiation Oncology, Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
A. Oliver Sartor, MD
Associate Professor of Medicine, Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute; Harvard Medical School, Boston, MA.
|
Disclosure Policy
It is the policy of ArcMesa Educators that our staff and faculty disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during presentations. Individuals who refuse to disclose will be disqualified from all aspects of this CME activity. ArcMesa Educators has policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
Disclaimer
©2009 ArcMesa Educators. All rights reserved. None of the contents may be reproduced in any form without prior written permission from ArcMesa Educators.
The views and opinions expressed in this activity are those of the faculty. They do not reflect the views of any other manufacturer of pharmaceuticals, ArcMesa Educators.
The recommendations made in this program are based upon a combination of randomized clinical trials, current guidelines, and the clinical practice experience of the participating faculty. Any medications, diagnostic procedures or treatments discussed by the faculty should not be utilized without evaluation of their patient’s conditions. Participants are urged to consult the full prescribing information on any drug mentioned in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.
Technical Support & Customer Services
ArcMesa Educators, LLC
Address: 666 Plainsboro Rd, Suite 440, Plainsboro, NJ 08536
Phone: 609-630-6100 | Fax: 609-630-6110 | Email: customer_services@arcmesa.org
|
